Enhanced stimulant and metabolic effects of combined ephedrine and caffeine

Clinical Pharmacology and Therapeutics

Volumn 75, Issue 4, 2004, Pages 259-273

  Haller, Christine A ^a,b   Jacob III, Peyton ^a   Benowitz, Neal L ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOCHEMICAL MARKER; CAFFEINE; CENTRAL STIMULANT AGENT; EPHEDRINE; FATTY ACID; GLUCOSE; HORMONE; INSULIN; LACTIC ACID; ORAL CONTRACEPTIVE AGENT;

ADRENALIN URINE LEVEL; ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG ELIMINATION; DRUG HALF LIFE; DRUG RESPONSE; DRUG URINE LEVEL; FATTY ACID BLOOD LEVEL; FEMALE; FLUSHING; GASTROINTESTINAL SYMPTOM; GLUCOSE BLOOD LEVEL; HEADACHE; HEART RATE; HORMONE BLOOD LEVEL; HUMAN; LIQUID CHROMATOGRAPHY; MALE; NORMAL HUMAN; PARESTHESIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEX DIFFERENCE; SIDE EFFECT; SWEATING; SYSTOLIC BLOOD PRESSURE; TACHYCARDIA; TANDEM MASS SPECTROMETRY; THORAX PAIN;

ADOLESCENT; ADULT; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; BLOOD PRESSURE; CAFFEINE; CARDIOVASCULAR SYSTEM; CENTRAL NERVOUS SYSTEM STIMULANTS; CONFIDENCE INTERVALS; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; EPHEDRINE; FEMALE; HEART RATE; HEMODYNAMIC PROCESSES; HUMANS; MALE; MIDDLE AGED; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY;

EID: 1842687888     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clpt.2003.11.375     Document Type: Article

References (39)

1. Shekelle P.G., Hardy M.L., Morton S.C., Maglione M., Mojica W.A., et al. Efficacy and safety of ephedra and ephedrine for weight loss and athletic performance. JAMA. 289:2003;1537-1545.
2. Haller C.A., Benowitz N.L. Adverse cardiovascular and central nervous system events associated with dietary supplements containing ephedra alkaloids. N Engl J Med. 343:2000;1833-1838.
3. Kockler D.R., McCarthy M.W., Lawson C.L. Seizure activity and unresponsiveness after hydroxycut ingestion. Pharmacotherapy. 21:2001;647-651.
4. Samenuk D., Link M.S., Homoud M.K., Contreras R., Theohardes R.C., Wang P.J., et al. Adverse cardiovascular events temporally associated with ma huang, an herbal source of ephedrine. Mayo Clin Proc. 77:2002;12-16.
5. Theoharides T.C. Sudden death of a healthy college student related to ephedrine toxicity from a ma-huang containing drink. J Clin Psychopharmacol. 17:1997;437-439.
6. Vahedi K., Domigo V., Amarenco R., Bousser M.G. Ischaemic stroke in a sportsman who consumed Mahuang extract and creatine monohydrate for body building. J Neurol Neurosurg Psychiatry. 68:2000;112-113.
7. Zahn K.A., Li R.L., Purssell R.A. Cardiovascular toxicity after ingestion of "herbal ecstasy" J Emerg Med. 17:1999;289-291.
8. URL: http://www.hhs.gov/news/press/2003pres/20031230.html
9. Zhang J.S., Tian Z., Lou Z.C. Quality evaluation of twelve species of Chinese ephedra (ma huang). Acta Pharm Sin. 24:1989;865-871.
10. Topic: guarana. The review of natural products. In: Facts and comparisons. St Louis (MO): Lippincott; 1991
11. Boozer C.N., Nasser J.A., Heymsfield S.B., Wang V., Chen G., Solomon J.L. An herbal supplement containing Ma huang-Guarana for weight loss a randomized, double-blind trial. Int J Obes Relat Metab Disord. 25:2001;316-324.
12. Boozer C.N., Daly P.A., Homel P., Solomon J.L., Blanchard D., Nasser J.A., et al. Herbal ephedra/caffeine for weight loss a 6-month randomized safety and efficacy trial. Int J Obes Relat Metab Disord. 26:2002;593-604.
13. Kalman D.S., Colker C.M., Shi Q., Swain M.A. Effects of a weight-loss aid in healthy overweight adults. Curr Ther Res Clin Exp. 61:2002;199-205.
14. Gurley B.J., Gardner S.F., White L.M., Wang P.L. Ephedrine pharmacokinetics after the ingestion of nutritional supplements containing ephedra sinica (ma huang). Ther Drug Monit. 20:1998;439-445.
15. White L.M., Gardner S.F., Gurley B.J., Marx M.A., Wang P.L., Estes M. Pharmacokinetics and cardiovascular effects of ma huang (Ephedra sinica) in normotensive adults. J Clin Pharmacol. 37:1997;116-122.
16. Haller C.A., Jacob P., Benowitz N.L. Pharmacology of ephedra alkaloids and caffeine after single dose dietary supplement use. Clin Pharmacol Ther. 71:2002;421-432.
17. Astrup A., Toubro S., Cannon S., Hein P., Madsen J. Thermogenic synergism between ephedrine and caffeine in healthy volunteers a double-blind, placebo-controlled study. Metabolism. 40:1991;323-329.
18. Dulloo A.G., Miller D.S. The thermogenic properties of ephedrine/methylxanthine mixtures human studies. Int J Obes Relat Metab Disord. 10:1986;467-481.
19. Bell D.G., Jacobs I., Zamecnik J. Effects of caffeine, ephedrine, and their combination on time to exhaustion during high-intensity exercise. Eur J Appl Physiol Occup Physiol. 77:1998;427-433.
20. Bell D.G., Jacobs I. Combined caffeine and ephedrine ingestion improves run times of Canadian Forces Warrior Test. Aviat Space Environ Med. 70:1999;325-329.
21. Bell D.G., McLellan T.M., Sabiston C.M. Effect of ingesting caffeine and ephedrine on 10-km run performance. Med Sci Sports Exerc. 34:2002;344-349.
22. Brown N.J., Ryder D., Branch R.A. A pharmacodynamic interaction between caffeine and phenylpropanolamine. Clin Pharmacol Ther. 50:1991;363-371.
23. Lake C.R., Rosenberg D.B., Gallant S., Zaloga G., Chernow B. Phenylpropanolamine increases plasma caffeine levels. Clin Pharmacol Ther. 47:1990;675-685.
24. Matthews D.R., Hosker J.P., Rudenski A.S., Naylor B.A., Treacher D.F., Turner R.C. Homeostasis model assessment insulin resistance and B-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologica. 28:1985;412-419.
25. Rowland M., Tozer T.N. Clinical pharmacokinetics concepts and application. 3rd ed. 1994;Lippincott Williams & Wilkins, Media (PA).
26. Boekema P.J., Samsom M., van Berge Henegouwen G.P., Smout A.J. Coffee and gastrointestinal function facts and fiction. A review. Scand J Gastroenterol Suppl. 230:1999;35-39.
27. Andersen T., Fogh J. Weight loss and delayed gastric emptying following a South American herbal preparation in overweight patients. J Hum Nutr Diet. 14:2001;243-250.
28. Patwardhan R.V., Desmond P.V., Johnson R.F., Schenker S. Impaired elimination of caffeine by oral contraceptive steroids. J Lab Clin Med. 95:1980;603-608.
29. Benowitz N.L. Clinical pharmacology of caffeine. Ann Rev Med. 41:1990;277-288.
30. Bowman W.C., Rand M.J. Textbook of pharmacology. 2nd ed. 1980;Blackwell Scientific Publications, London.
31. Patil P.N., Tye A., Lapidus J.B. A pharmacological study of the ephedrine isomers. J Pharmacol Exp Ther. 148:1965;158-168.
32. Keijzers G.B., De Galan B.E., Tack C.J., Smits P. Caffeine can decrease insulin sensitivity in humans. Diabetes Care. 25:2002;364-369.
33. Zsoter T., Tom H., Kraml M., Dvornik D. Adrenergic beta receptors and plasma free fatty acids. J Pharm Exp Ther. 152:1966;425-431.
34. Astrup A., Madsen J., Holst J.J., Christensen N.J. The effect of chronic ephedrine treatment on substrate utilization, the sympathadrenal activity, and energy expenditure during glucose-induced thermogenesis in man. Metabolism. 35:1986;260-265.
35. Patwardhan R.V., Desmond P.V., Johnson R.F., Dunn G.D., Robertson D.H., Hoyumpa A.M., et al. Effects of caffeine on plasma free fatty acids, urinary catecholamines, and drug binding. Clin Pharmacol Ther. 28:1980;398-403.
36. Luzier A.B., Nawarskas J.J., Anonuevo J., Wilson M.F., Kazierad D.J. The effects of gender on adrenergic receptor responsiveness. J Clin Pharmacol. 38:1998;618-624.
37. Abdel-Rahman A.R., Merrill R.H., Wooles W.R. Gender-related differences in the baroreceptor reflex control of heart rate in normotensive adults. J Appl Physiol. 77:1994;603-613.
38. Young R., Gabryszuk M., Glennon R.A. (-)Ephedrine and caffeine mutually potentiate one another's amphetamine-like stimulus effects. Pharmacol Biochem Behav. 61:1998;169-173.
39. Gauvin D.V., Moore K.R., Youngblood B.D., Holloway F.A. The discriminative stimulus properties of legal, over-the-counter stimulants administered singly and in binary and ternary combinations. Psychopharmacol (Berl). 110:1993;309-319.